Barclays’s ResMed RMD Stock Holding History

Barclays’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$449K	Sell	2,000 -87,500	-98%	-$21.8M	﹤0.01%	3253
2025 Q4	$21.6M	Buy	89,500 +82,500	+1,179%	+$21.1M	0.01%	1221
2025 Q3	$1.92M	Sell	7,000 -48,000	-87%	-$13.1M	﹤0.01%	2924
2025 Q2	$14.2M	Sell	55,000 -50,000	-48%	-$11.9M	﹤0.01%	1330
2025 Q1	$23.5M	Buy	105,000 +55,000	+110%	+$12.8M	0.01%	955
2024 Q4	$11.4M	Buy	50,000 +44,600	+826%	+$10.7M	﹤0.01%	1476
2024 Q3	$1.32M	Buy	+5,400	New	+$1.21M	﹤0.01%	3166
2024 Q2	–	Sell	-82,500	Closed	-$16.3M	–	5235
2024 Q1	$16.3M	Buy	+82,500	New	+$15.1M	0.01%	1098
2020 Q3	–	Sell	-5,000	Closed	-$960K	–	5524
2020 Q2	$960K	Sell	5,000 -6,500	-57%	-$1.06M	﹤0.01%	2804
2020 Q1	$1.69M	Buy	11,500 +5,200	+83%	+$828K	﹤0.01%	2433
2019 Q4	$976K	Buy	6,300 +2,500	+66%	+$360K	﹤0.01%	3701
2019 Q3	$513K	Sell	3,800 -700	-16%	-$91.7K	﹤0.01%	4232
2019 Q2	$549K	Sell	4,500 -7,300	-62%	-$809K	﹤0.01%	4237
2019 Q1	$1.23M	Buy	11,800 +8,700	+281%	+$898K	﹤0.01%	3178
2018 Q4	$353K	Buy	3,100 +1,000	+48%	+$107K	﹤0.01%	4143
2018 Q3	$242K	Buy	2,100 +1,300	+163%	+$142K	﹤0.01%	4855
2018 Q2	$83K	Sell	800 -2,500	-76%	-$253K	﹤0.01%	5361
2018 Q1	$325K	Buy	3,300 +400	+14%	+$37.8K	﹤0.01%	4391
2017 Q4	$246K	Buy	2,900 +600	+26%	+$49.6K	﹤0.01%	4511
2017 Q3	$177K	Buy	2,300 +1,100	+92%	+$84.1K	﹤0.01%	4528
2017 Q2	$93K	Sell	1,200 -800	-40%	-$57.2K	﹤0.01%	4959
2017 Q1	$144K	Sell	2,000 -900	-31%	-$62.2K	﹤0.01%	4601
2016 Q4	$180K	Sell	2,900 -52,600	-95%	-$3.22M	﹤0.01%	4301
2016 Q3	$3.6M	Buy	+55,500	New	+$3.69M	﹤0.01%	1544
2016 Q2	–	Sell	-41,100	Closed	-$2.34M	–	6590
2016 Q1	$2.34M	Buy	41,100 +34,600	+532%	+$1.96M	﹤0.01%	1779
2015 Q4	$345K	Sell	6,500 -6,900	-51%	-$389K	﹤0.01%	3492
2015 Q3	$670K	Sell	13,400 -5,900	-31%	-$318K	﹤0.01%	3090
2015 Q2	$1.08M	Buy	19,300 +15,200	+371%	+$959K	﹤0.01%	2816
2015 Q1	$291K	Sell	4,100 -800	-16%	-$52K	﹤0.01%	4063
2014 Q4	$274K	Sell	4,900 -4,400	-47%	-$230K	﹤0.01%	4385
2014 Q3	$456K	Sell	9,300 -3,900	-30%	-$199K	﹤0.01%	4027
2014 Q2	$660K	Buy	13,200 +4,000	+43%	+$198K	﹤0.01%	3721
2014 Q1	$405K	Buy	9,200 +8,100	+736%	+$364K	﹤0.01%	4134
2013 Q4	$52K	Sell	1,100 -22,500	-95%	-$1.14M	﹤0.01%	6157
2013 Q3	$1.23M	Buy	23,600 +18,400	+354%	+$893K	﹤0.01%	3123
2013 Q2	$235K	Buy	+5,200	New	+$247K	﹤0.01%	5013

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Barclays's RMD Position: Q1 2026 in Review

Barclays reduced its ResMed (RMD) stake by 7% in Q1 2026, selling an estimated $6.24M and leaving 334,114 shares worth $75M. The position accounts for 0.02% of the portfolio, ranked #593.

Barclays first reported a position in RMD in Q2 2013 and has held it in 52 quarters since. The position peaked at $191M in Q2 2025. 939 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

Barclays held 334,114 shares of ResMed worth $75M as of Q1 2026.
Barclays sold 25,053 ResMed shares in Q1 2026, an estimated $6.24M.
ResMed made up 0.02% of Barclays's portfolio in Q1 2026, its #593 holding.
Barclays first reported a position in ResMed in Q2 2013 and has held it in 52 quarters since.
Barclays's ResMed position peaked at $191M in Q2 2025.
939 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.